Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) EPS (Weighted Average and Diluted) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.03 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$0.03 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.92 through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.09 for FY2025, 14.17% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.03 at Actinium Pharmaceuticals, up from -$0.16 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.03 in Q4 2025, with the low at -$0.58 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.34, with a median of -$0.33 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 84.39% in 2023, then surged 56.76% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.39 in 2021, then dropped by 20.1% to -$0.47 in 2022, then grew by 29.44% to -$0.33 in 2023, then dropped by 12.12% to -$0.37 in 2024, then surged by 91.89% to -$0.03 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.03, -$0.16, and -$0.22 for Q4 2025, Q3 2025, and Q2 2025 respectively.